Engineers Gate Manager LP Gritstone Bio, Inc. Transaction History

Engineers Gate Manager LP

$4.86 Billion
Q3 2024

A detailed history of Engineers Gate Manager LP transactions in Gritstone Bio, Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 18,630 shares of GRTS stock, worth $558. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,630

Previous 18,630 -0.0%

Holding current value

$558

Previous $11,000 9.09%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.62 - $2.35 $11,550 - $43,780	18,630 New	18,630 $11,000
Q4 2023 Feb 14, 2024	SELL	$1.28 - $2.85 $39,361 - $87,640	-30,751 Reduced 56.72%	23,464 $47,000
Q3 2023 Nov 14, 2023	BUY	$1.19 - $2.26 $44,473 - $84,462	37,373 Added 221.9%	54,215 $93,000
Q2 2023 Aug 14, 2023	BUY	$1.66 - $3.03 $27,957 - $51,031	16,842 New	16,842 $32,000
Q4 2022 Feb 14, 2023	SELL	$2.17 - $3.92 $5,045 - $9,114	-2,325 Reduced 18.62%	10,161 $35,000
Q3 2022 Nov 14, 2022	SELL	$2.46 - $4.75 $44,063 - $85,082	-17,912 Reduced 58.92%	12,486 $32,000
Q2 2022 Aug 15, 2022	BUY	$1.77 - $4.34 $53,804 - $131,927	30,398 New	30,398 $74,000
Q4 2021 Feb 14, 2022	SELL	$8.76 - $13.71 $290,227 - $454,226	-33,131 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.41 - $13.54 $39,940 - $84,367	6,231 Added 23.16%	33,131 $358,000
Q2 2021 Aug 16, 2021	BUY	$8.13 - $10.2 $136,584 - $171,360	16,800 Added 166.34%	26,900 $246,000
Q1 2021 May 17, 2021	BUY	$4.07 - $27.11 $41,107 - $273,811	10,100 New	10,100 $95,000
Q3 2020 Nov 16, 2020	SELL	$2.63 - $8.09 $45,236 - $139,148	-17,200 Closed	0 $0
Q2 2020 Aug 17, 2020	BUY	$5.69 - $8.17 $97,868 - $140,524	17,200 New	17,200 $114,000

Others Institutions Holding GRTS

# of Institutions

Shares Held

35.4M

Call Options Held

395K

Put Options Held

132K

View Full List

About Gritstone bio, Inc.

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

More about GRTS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.

Account

Engineers Gate Manager LP Gritstone Bio, Inc. Transaction History